Christopher Pechock Net Worth
The estimated Net Worth of Christopher Pechock is at least $1.71 Billion dollars as of 27 March 2019. Mr. Pechock owns over 34,247 units of MYOS RENS Technology stock worth over $372,878 and over the last 15 years he sold MYOS stock worth over $1,705,890,684. In addition, he makes $0 as Independent Director at MYOS RENS Technology.
Mr. Pechock MYOS stock SEC Form 4 insider trading
Christopher has made over 4 trades of the MYOS RENS Technology stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 34,247 units of MYOS stock worth $50,001 on 27 March 2019.
The largest trade he’s ever made was selling 56,979,062 units of MYOS RENS Technology stock on 6 August 2007 worth over $1,381,742,254. On average, Christopher trades about 7,909,707 units every 572 days since 2005. As of 27 March 2019 he still owns at least 257,157 units of MYOS RENS Technology stock.
You can see the complete history of Mr. Pechock stock trades at the bottom of the page.
Christopher Pechock biography
Christopher R. Pechock (Chris) is Independent Director of the Company. Mr. Pechock was a partner at Matlin Patterson Global Advisers, a global alternative asset manager, since its inception in July 2002 through September 2017. From November 1998 to July 2002, Mr. Pechock served as a member of the Global Distressed Securities Group Credit Suisse (NYSE:CS). From January 1997 to October 1998, Mr. Pechock served as a Portfolio Manager and Research Analyst at Turnberry Capital Management, L.P. Prior to that, Mr. Pechock served as a Portfolio Manager at Eos Partners, L.P. (February 1996 to December 1996), a Vice President and high yield analyst at PaineWebber Inc. (May 1993 to January 1996) and an analyst in risk arbitrage at Wertheim Schroder & Co., Incorporated (August 1987 to April 1991). Mr. Pechock received a BA in Economics from the University of Pennsylvania and an MBA from the Columbia University Graduate School of Business.
How old is Christopher Pechock?
Christopher Pechock is 54, he’s been the Independent Director of MYOS RENS Technology since 2014. There are 7 older and no younger executives at MYOS RENS Technology. The oldest executive at MYOS RENS Technology, Inc. is Christopher Dewey, 75, who is the Independent Director.
What’s Christopher Pechock’s mailing address?
Christopher’s mailing address filed with the SEC is 520 MADISON AVENUE, , NEW YORK, NY, 10022.
Insider trading at MYOS RENS Technology
Over the last 7 years, insiders at MYOS RENS Technology have traded over $0 worth of MYOS RENS Technology stock and bought 953,035 units worth $1,279,258 . The most active insider traders include Christopher Pechock, Joseph Mannello, and Louis J. Aronne. On average, MYOS RENS Technology executives and independent directors trade stock every 88 days with the average trade being worth of $50,715. The most recent stock trade was executed by Christopher Pechock on 27 March 2019, trading 34,247 units of MYOS stock currently worth $50,001.
What does MYOS RENS Technology do?
MYOS RENS Technology, Inc. engages in the discovery, development, and commercialization of advanced nutrition products, functional foods, and other technologies aimed at maintaining or improving the health and performance of muscle tissue. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.
What does MYOS RENS Technology’s logo look like?
Complete history of Mr. Pechock stock trades at MYOS RENS Technology and Huntsman
MYOS RENS Technology executives and stock owners
MYOS RENS Technology executives and other stock owners filed with the SEC include:
- Joseph Mannello, Chief Executive Officer, Director
- Eric Zaltas, Independent Director
- John Nosta, Independent Director
- Christopher Dewey, Independent Director
- Christopher Pechock, Independent Director
- Victor Mandel, Independent Director
- Louis Aronne, Independent Director
- Ren Ren, Director Global Chairman
- Robert Hariri, Independent Chairman of the Board
- Sapna Srivastava, Director
- Joseph Dos Santos, Chief Financial Officer
- Kenrick Bryce Toussaint, Chief Executive Officer
- Buzz Aldrin, Director
- Zhengguang Lyu, Director
- Robert C. Jr. Ashton, Chief Medical Officer
- Peter Diamandis, Director
- John Craig Venter, Director
- Peter Levy, COO & Executive VP
- Carl De Freitas, Interim CFO
- Glen R. Fleischer, Chief Executive Officer
